Covid-19

#Covid-19 #Immunology / Virology & Vaccines #Vaccines

This week in drug discovery (28 June – 2 July)

News round-up by DDW’s Megan Thomas for 28 June – 2 July This week in news The last year and a half has accelerated the virology scene at a pace that was previously unseen, and not exclusively for Covid-19. Vaccines continue to be an unquestionably important part of how we… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Positive new data for J&J Covid vaccine against Delta variant

Johnson & Johnson has announced data that demonstrated its single-shot Covid-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of… Read More

#News #Trending News

#Covid-19 #Drug development #Drug discovery #mRNA

Can antiviral oligonucleotides better prepare us for the next pandemic?

Todd Stawicki, Global Marketing Manager for MS Biopharma at SCIEX, offers an in-depth analysis of oligonucleotides and their role in preparing for the next pandemic Covid-19, the disease caused by SARS-CoV-2, is arguably the greatest public health threat in a generation. It has temporarily paralysed our just-in-time economy1,2 and highlighted many… Read More

#Exclusive Content #News

#Antibodies #Complex medicines #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug targets #Life sciences

Financial benefit of complex medicines to UK life sciences

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK… Read More

#News

#Antibodies #AstraZeneca #Biomedical research #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccines

Covid antibody levels vary according to vaccine type

Two doses of the Oxford-AstraZeneca Covid-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains. These laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre are published… Read More

#Covid-19 #News #Trending News

#Antigen #Awards #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Winners of ‘The Best Covid-19 Responder’ announced

The Native Antigen Company has won ‘The Best Covid-19 Responder’ at the OBN 2020 Awards. The award recognises the Company’s contribution to the fight against Covid-19. The Native Antigen Company has utilised its expertise in developing high-quality reagents to play a major role in the global response to SARS-CoV-2. In… Read More

#News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Biden to invest US$3 bn to boost Covid-19 drug discovery

As part of the American Rescue Plan, the Biden Administration is investing more than US$3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of the whole-of-government strategy to develop the next generation of Covid-19 treatments. Through collaboration within the US Department of Health and Human… Read More

#News #Trending News

#Clinical trials #Covid-19 #CureVac #Immunology / Virology & Vaccines

CureVac mRNA vaccine only 47% effective

CureVac has announced results of the second interim analysis of its international pivotal Phase IIb/III study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation Covid-19 vaccine candidate, CVnCoV. At second interim analysis, statistical success criteria were not met. In the unprecedented context of at least 13 variants circulating… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug delivery #Drug development

Corticosteroids could treat Covid-19 complications in children

Corticosteroids may be an effective treatment for children who develop a rare but serious condition after Covid-19 infection. This is the finding of an international study of 614 children, published in the New England Journal of Medicine, led by Imperial College London. All children in the study developed a serious… Read More

#News

#AstraZeneca #Biopharmaceuticals #Covid-19 #Immunology / Virology & Vaccines

AstraZeneca vaccine is 92% effective against Delta variant

New data from Public Health England (PHE) demonstrated AstraZeneca’s Covid-19 vaccine offers high levels of protection against the Delta variant (B.1.617.2; formerly the ‘Indian’ variant). Real world data from PHE, published as a pre-print, demonstrated two doses of AstraZeneca are 92% effective against hospitalisation due to the Delta variant and… Read More

#Covid-19 #News #Trending News

#Clinical trials #Covid-19 #Data #GlobalData #Immunology / Virology & Vaccines

Covid-19 vaccine and therapeutic trials show different trends

Since Covid-19 was officially declared a pandemic by the World Health Organization (WHO), the peak in total number of clinical trials for the virus was seen in the month of April 2020. There has since been a steady decrease in new clinical trial investigations, except for the months of December… Read More

#News #Trends & Analysis

#Covid-19 #Immunology / Virology & Vaccines #Public health #Sinovac #Vaccines

Has China approved a Covid-19 vaccine for three year olds?

The New York Times has reported that the Chairman of the Chinese drug maker Sinovac said China had approved the company’s Covid-19 vaccine for children as young as three, which the media outlet explains would make the country the first in the world to endorse a vaccine for children of… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug discovery

Aspirin does not improve survival for Covid-19 patients

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with Covid-19, who are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccine candidate

Can Pfizer-BioNTech vaccine target the Delta variant?

Levels of antibodies in the blood of vaccinated people that can recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug development #Immunology / Virology & Vaccines

Is a needle-free Covid-19 vaccination possible?

University of Queensland scientists have successfully protected mice from the Covid-19 virus by administering a US-developed vaccine candidate with a ‘patch’, rather than a needle. The University of Texas Hexapro vaccine candidate, delivered via the UQ-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP), provided protection against Covid-19 disease with a single,… Read More

#Covid-19 #News #Trending News

#Clinical trial #Clinical Trial Authorisation #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna initiates rolling submission of Biologics License Application (BLA)

Moderna has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older. Stéphane Bancel, Chief Executive Officer of Moderna, said: “We look forward… Read More

#News #Trending News